Long Non-Coding RNA: Potential Diagnostic and Therapeutic Biomarker for Major Depressive Disorder.
Long Non-Coding RNA: Potential Diagnostic and Therapeutic Biomarker for Major Depressive Disorder.
复制标题
长的非编码RNA：重度抑郁症的潜在诊断和治疗生物标志物。
DOI：
10.12659/msm.899372
复制
发表时间：
2016-12-31
期刊：
影响因子：
--
通讯作者：
Cheng Z
中科院分区：
文献类型：
--
作者：
Cui X;Sun X;Niu W;Kong L;He M;Zhong A;Chen S;Jiang K;Zhang L;Cheng Z
诊断抑郁症的标准是基于患者或监护人的行为观察和症状自我报告，而无需对该疾病进行任何生物学验证。本研究旨在鉴定外周血单个核细胞（PBMC）中的长链非编码RNA（lncRNA）作为诊断和治疗重度抑郁症（MDD）的可靠和预测性生物标志物。我们使用了人类lncRNA 3.0微阵列分析（涵盖30，586种人类lncRNA），使用了来自5名MDD患者和5名对照的PBMC。在MDD患者的PBMC中鉴定差异表达的lncRNA，其中10个候选lncRNA被选择用于在138名MDD患者和63名健康对照的较大队列中进行实时定量逆转录聚合酶链反应（qRT-PCR）分析。然后在138例接受标准抗抑郁治疗的MDD患者中，随机选择30例在抗抑郁治疗3周和6周后进行lncRNA表达复检和药理学评估。六种lncRNA与对照患者相比，在MDD患者中，TCONS_00019174、ENST 00000566208、NONHSAG 045500、ENST 0000517573、NONHSAT 034045和NONHSAT 142707）显著下调，并且这六种lncRNA病例的受试者工作曲线（ROC）下的面积，为0.719（95%置信区间（CI）：0.617-0.821）。这6种lncRNA的表达在性别（p>0.05）和年龄（p>0.05）之间均无差异。这些结果表明，6种lncRNA在PBMC中的组合表达可作为MDD临床诊断和治疗反应的潜在生物标志物。
The criteria for diagnosing depression are based on behavioral observation and self-reporting of symptoms by the patients or guardians without any biological validation of the disease. This study aimed to identify long non-coding RNAs (lncRNAs) in peripheral blood mononuclear cells (PBMCs) as robust and predictive biomarkers for diagnosis and therapy response in major depressive disorder (MDD). We used human lncRNA 3.0 microarray profiling (which covers 30,586 human lncRNAs), using PBMCs from five MDD patients and five controls. Differentially expressed lncRNAs in the PBMCs of MDD patients were identified, of which 10 candidate lncRNAs were selected for real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis in a larger cohort of 138 MDD patients and 63 healthy controls. Then among the 138 MDD patients who received standard antidepressant treatment, 30 were randomly selected for lncRNAs expression retesting and symptomatology assessments after three-weeks and six-weeks of antidepressant treatment. Six lncRNAs (TCONS_00019174, ENST00000566208, NONHSAG045500, ENST00000517573, NONHSAT034045, and NONHSAT142707) were significantly downregulated in MDD patients compared to control patients, and the area under the receiver operator curve (ROC) of these six lncRNAs cases, combined, was 0.719 (95% confidence interval (CI): 0.617–0.821). There was no difference in the expression of these six lncRNAs based on gender (p>0.05) or age (p>0.05). These results suggest that the combined expression of six lncRNAs in PBMCs may serve as a potential biomarker for diagnosis and therapy response of MDD in the clinical setting.